-The Business Standard Confusion over clinical trial compensation norms Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration. The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials...

-Frontline The National Advisory Council recommendations seem to be making a strong case for a major role for the private sector in the delivery of health care. THE recommendations for universal health coverage drawn up by the National Advisory Council (NAC), headed by United Progressive Alliance (UPA) chairperson Sonia Gandhi, push for public-private partnerships (PPPs) in the health delivery system but not for any inbuilt mechanisms for accountability. The NAC also...

-The Business Standard The new price caps for 191 essential drugs are likely to introduce serious distortions in the market for these medicines The National Pharmaceutical Pricing Authority, or NPPA, has announced new price caps for 191 essential drugs that are 10 to 50 per cent lower than the current prices. Drug makers have 45 days to recall the earlier batches and send out new ones with the lower price tags. This...

-The Hindu The current market prices are essentially over and above the actual cost of production - a difference that could run from 100 per cent to 5,600 per cent, depending upon various therapeutic categories In a liberalised market economy, do we need price controls on drugs? Policymakers and the Pharmaceutical Industry do not think so. They believe that price controls are an inefficient tool that distorts resource allocation, squeezes revenue, reduces...

-The Hindu     The much-awaited Drug (Prices Control) Order 2013 has disappointed millions of patients, as it lacks a fair formula to fix the price ceiling and leaves important drug classes out of regulation. The result: High out-of-pocket spending on medicines will continue As far as intentions go, the Drug (Prices Control) Order 2013 is aimed at making critical drugs affordable and available to the public, while preserving a rationale for manufacture by...